Trasylol recall issued
Although Bayer AG agreed to stop marketing their heart surgery injection Trasylol in November 2007, they are now removing any remaining stock of the drug from the U.S. market following a study published in the New England Journal of Medicine. The Trasylol recall was issued after data from a Canadian study confirmed that those treated with the injection faced a substantial increased risk of death.
>>INFORMATION: Trasylol Recall Lawsuits
Trasylol, also known as an aprotinin injection, was widely used for many years during cardiac bypass surgery to control bleeding during surgery. However, safety concerns began to surface in 2006 after a study suggested that those treated with the drug may face an increased risk of death, heart attack, stroke or kidney failure.
In October 2007, a Canadian study known as BART (Blood conservation using Antifibrinolytics in Randomized Trial) was stopped by researchers after preliminary results found that those treated with Trasylol had a high death rate when compared head-to-head against those who were given cheaper alternative medications.
On Wednesday, the New England Journal of Medicine released an analysis of data from the study which involved 2,300 people. Researchers found that six percent of those given a Trasylol injection died within 30 days of heart surgery, which was a 54% greater risk of death when compared to those taking two other anti-bleeding drugs, Amicar and Cyklokapron.
TRASYLOL RECALL LAWSUITS
Bayer currently faces hundreds of potential Trasylol lawsuits which are being pursued on behalf of those injured by the heart surgery injection. In addition to marketing an unreasonably dangerous medication that did not contain adequate warnings, the drug maker has also been accused of actively covering up damaging data about the safety of the drug.
Although most people who were given aprotinin are unaware of the name of the injection they received, the Trasylol lawyers at Saiontz & Kirk, P.A. are reviewing potential cases for anyone who suffered a heart attack, stroke, kidney failure or death within 30 days of heart bypass surgery. To review a potential claim, request a free consultation.
